pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Aug 14·1 min read
save

FDA releases weekly update on user fee letters and new HHS regulatory agenda

Aug 14, 2026·read at raps ↗RegulatoryNeutral

The FDA's latest weekly briefing highlighted the release of user fee commitment letters, which outline the agency's financial planning for upcoming fiscal periods.

It also introduced a new regulatory agenda from the Department of Health and Human Services, signaling upcoming policy priorities for drug and device oversight.

The update serves as a concise source for professionals tracking regulatory changes, linking to relevant documents and commentary from industry observers.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “This Week at FDA: User fee commitment letters, new HHS regulatory agenda, and more”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoRecon: FDA approves drugs for Parkinson’s, bile duct cancer, rare soft tissue disease; Merck, Daiichi scrap application for ADC ...raps
  • 1d agoAsia-Pacific Roundup: Indian government approves adverse event monitoring plan for transplantation productsraps
  • 1d agoConvergence: CBER expert offers tips for effective BLA submissionsraps
  • 1d agoBsUFA commitment letter outlines changes to FDA’s biosimilar review programraps
  • 1d agoCDER director, expert discuss scientific, legal challenges to bringing generic GLP-1s to marketraps